National Development and Reform Commission

Reform in China’s Pharmaceuticals Sector - What the Doctor Ordered?

Reform in China’s Pharmaceuticals Sector - What the Doctor Ordered?

Fewer restrictions on drug pricing and greater access for foreign companies may make for a healthier China, and bring both potential growth and growing pains to the pharmaceutical industry—a sector analysts expect to be worth upwards of $300 billion by 2020.

Tags

R&D

NDRC 'Actively' Investigating AML Cases Despite Media Silence

NDRC 'Actively' Investigating AML Cases Despite Media Silence

A lack of recent news about competition-related investigation cases should not be misinterpreted as a lull in enforcement activity related to China’s Antimonopoly Law (AML), a National Development and Reform Commission (NDRC) official stated at a recent USCBC-sponsored event.

Tags

AML
IP
Subscribe to RSS - National Development and Reform Commission